Home/Pipeline/TW001

TW001

Alzheimer's Disease

Phase 2Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active

Company

Treeway

About Treeway

Treeway is a patient-founded, Netherlands-based biotech focused on the formidable challenge of treating neurodegenerative diseases like ALS and Alzheimer's. Its lead asset, TW001, is an oral formulation of edaravone being developed for Alzheimer's disease, with Phase 2 results recently accepted for a late-breaking presentation. The company operates with a lean, expert team and leverages strategic academic and industry collaborations to advance its preclinical and clinical pipeline.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis (ALS)Alzheimer's Disease Neurodegenerative Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active